脑脊液葡萄糖脑苷脂酶活性与帕金森病患者发生痴呆风险的相关性
基于挪威西南部人群的帕金森病前瞻性队列(117例患者、50名对照,随访至10年),诊断时脑脊液葡萄糖脑苷脂酶(GCase)活性在帕金森病患者中低于对照,且基线GCase活性较低与未来发生帕金森病痴呆风险增加相关(HR 1.15,95%CI 1.03-1.28,p=0.014)。
要点
- 诊断时脑脊液GCase活性在帕金森病患者中低于对照。
- 基线GCase活性较低与10年内发生帕金森病痴呆风险增加相关。
- 该关联为Ⅲ级证据,对靶向GCase的试验设计有意义。
核心结论
- 诊断时脑脊液GCase活性降低与帕金森病后来发生痴呆的风险增加相关,提供Ⅲ级证据。
研究设计与样本
- 基于挪威西南部正在进行的、以人群为基础的纵向ParkWest研究,帕金森病患者前瞻性随访至10年;诊断时采集脑脊液并检测GBA携带状态;对照为无神经退行性疾病者;采用参数加速失效时间模型分析GCase活性与无痴呆生存的关联。
- 共纳入117例帕金森病患者(平均年龄67.2岁,含12例GBA非同义变异携带者)和50名对照(平均年龄64岁)。
主要发现
- 诊断时GCase活性:帕金森病患者伴GBA变异者(0.92 ± 0.40 mU/mg,n=12)或不伴GBA变异者(1.00 ± 0.37 mU/mg,n=105)均低于对照(1.20 ± 0.35 mU/mg,n=50)。
- 诊断时GCase活性在10年内发生痴呆的帕金森病患者(0.85 ± 0.27 mU/mg,n=41)低于未发生痴呆者(1.07 ± 0.40 mU/mg,n=76,p=0.001)。
- 基线GCase活性每降低0.1单位与帕金森病痴呆更快发生相关(风险比1.15,95%CI 1.03-1.28,p=0.014)。
关键数值与推荐
- 帕金森病痴呆诊断依据运动障碍学会(Movement Disorder Society)标准。
- GCase活性采用经过验证的检测方法测量。
临床怎么用
- 早期脑脊液GCase活性与帕金森病痴呆长期进展的关联对靶向GCase治疗的临床试验设计和患者管理具有重要意义。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Variations in the glucocerebrosidase gene (GBA) are common risk factors for Parkinson disease (PD) and dementia in PD (PDD) and cause a reduction in the activity of the lysosomal enzyme glucocerebrosidase (GCase). It is anticipated that GCase dysfunction might contribute to a more malignant disease course and predict cognitive impairment in PD, although evidence is lacking. We aimed to discover whether CSF GCase activity is altered in newly diagnosed patients with PD and associated with future development of dementia. METHODS: Patients with PD were participants of the ongoing population-based longitudinal ParkWest study in Southwestern Norway and were followed prospectively for up to 10 years. CSF was collected at diagnosis, and GBA carrier status was obtained. Control samples were from persons without neurodegenerative disorders. GCase activity was measured using a validated assay. PD dementia diagnosis was set according to the Movement Disorder Society criteria, and parametric accelerated failure time models were applied to analyze the association of GCase activity with dementia-free survival. RESULTS: This study enrolled 117 patients with PD (mean age 67.2 years, including 12 GBA non-synonymous variant carriers) and 50 control participants (mean age 64 years). At the time of diagnosis, GCase activity was reduced in patients with PD with (mean ± SD, 0.92 ± 0.40 mU/mg, n = 12) or without GBA variations (1.00 ± 0.37 mU/mg, n = 105) compared with controls (1.20 ± 0.35, n = 50). GCase activity at the time of diagnosis was lower in patients with PD who developed dementia within 10 years (0.85 ± 0.27 mU/mg, n = 41) than in those who did not (1.07 ± 0.40 mU/mg, n = 76, p = 0.001). A 0.1-unit reduction in baseline GCase activity was associated with a faster development of PDD (hazard ratio 1.15, 95% CI 1.03-1.28, p = 0.014). DISCUSSION: The association of early CSF GCase activity with long-term progression to PD dementia will have important implications for the design of clinical trials for GCase targeting therapies and patient management. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that reduced CSF GCase activity at the time of PD diagnosis is associated with an increased risk for later development of PDD.
引用
- Oftedal L, Maple-Grødem J, Dalen I, et al. Association of CSF Glucocerebrosidase Activity With the Risk of Incident Dementia in Patients With Parkinson Disease. Neurology. 2022. PMID: 36253102. doi:10.1212/WNL.0000000000201418
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。